Physician profile
Sandra Mancilla
NPI 1033247325
$5,766.75
in general payments reported to CMS, 2019-2025
28 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $963 · 2021: $483 · 2022: $739 · 2023: $1,352 · 2024: $805 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,293.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $581.32 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $512.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $468.54 | 2020-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $423.12 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $254.29 | 2019-2020 | |
| Pfizer INC. | $231.19 | 2019-2025 | |
| Astellas Pharma US INC | $217.26 | 2019-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $195.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.62 | 2019-2022 | |
| Stryker Corporation | $150.31 | 2023 | Mako |
| Eisai INC. | $149.25 | 2020 | |
| Vertos Medical, INC. | $147.95 | 2023 | Mild Device Kit |
| Biohaven Pharmaceuticals, INC. | $134.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.55 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $110.00 | 2023 | Yupelri |
| Lundbeck LLC | $97.35 | 2021-2023 | Rexulti |
| Exact Sciences Corporation | $84.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $74.79 | 2020-2022 | |
| Abbvie INC. | $73.68 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $69.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $65.26 | 2019-2024 | Gardasil, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $52.78 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.24 | 2020-2025 | Xifaxan |
| Globus Medical, INC. | $26.59 | 2025 | Senza |
| Shionogi INC | $14.42 | 2021 | |
| Medtronic Vascular, INC. | $11.12 | 2020 | |
| Athena Bioscience, LLC | $10.50 | 2024 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Mancilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.